LONDON (Alliance News) - GlaxoSmithKline PLC said Tuesday its Phase III study for drug darapladib in the treatment of acute coronary syndrome failed to meet its primary endpoint of reducing major coronary events compared to a placebo when added to standard care.
The company said that the overall safety profile of the drug showed no major safety concerns.
Glaxo said that it would further analyse the data from the study to better understand its findings.
"We are disappointed that the outcome of this second phase III study with darapladib does not support a regulatory submission in atherosclerosis," said President of Research and Development Patrick Vallance in a statement.
Darapladib is not currently approved for use in any country.
Shares in Glaxo are not yet traded Tuesday. They last traded Monday at 1,617.90 pence.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
